RECENT PUBLICATIONS:

1. Rini JN, Vallabhajosula S, Hurley JR, Becker DV and Goldsmith SJ. Thyroid uptake of liquid versus capsule I-131 tracers in hyperthyroid patients treated with liquid I-131. Thyroid (United States) 1999; 9(4):347-52

2. Smith-Jones PM. Vallabhajosula S, Bastidas D, Hunter C, Navarro V, Bander NH and Goldsmith SJ. Preclinical studies with 131I and 111In labeled monoclonal antibodies, specific for either the intracellular or extra-cellular domains of prostate specific membrane antigen. J Label Comp Radioph 1999;42:suppl 1,s701-703

3. Smith-Jones PM, Vallabhajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, Bander NH. In vitro Characterization of Radiolabeled Monoclonal Antibodies Specific for the Extracellular Domain of Prostate-specific Membrane Antigen. Cancer Res 2000; 60:5237-5243.

4. Daimond JA, Machac J, Vallabhajosula S, Henzlova MJ, Ali MK, Mezrow CK, Gandses A, Travis A & Phillips RA. Validation in the canine model of a new non-ivasive method of measuring coronary blood flow reserve: split dose thallium-201 rest/stress imaging. International J Cardiovascular Imag 2001;17:145-152.

5. Smith-Jones PM, Vallabhajosula S, St. Omer S, Navarro V, Goldsmith SJ, Bander NH, 177Lu-DOTA-HuJ591: A new Radiolabeled monoclonal antibody (MAb) for targeted therapy of prostate cancer. J Label Compds Radiopharm 2001;44:Suppl 1:90-92.

6. Kostakoglu L, Leonard JP, Kuji I, Coleman M, Vallabhajosula S, Goldsmith SJ. Comparison of F-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in lymphoma. Cancer 2002;94:879-888.

7. Yao D, Trabulsi EJ, Kostakoglu L, Vallabhajosula S, Joyce MA, Nanus DM, Milowsky M, Liu H, Goldsmith, SJ. The utility of monoclonal antibodies in the imaging of prostate cancer. Sem Urol Onc 2002;20:211-218.

8. Smith-Jones PM, Vallabhajosula S, Navarro V, et al: Radiolabeled monoclonal antibodies specific to the extra-cellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med 2003;44:610-617.

9. Nanus D, Milowsky MI, Kostakoglu L, Smith-Jones PM, Vallabahajosula S, Goldsmith SJ and Bander NH: Clinical use of Monoclonal Antibody HuJ591 Therapy: Targeting Prostate Specific Membrane Antigen. J Urol, 2003:170:S84-S89.

10. Bander, NH, Trabulsi E, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P, Joyce MA, Milowsky M, Nanus DM and Goldsmith SJ: Targeting Metastatic Prostate Cancer with Radiolabeled Monoclonal Antibody J591 in the Extracellular Domain of Prostate Specific Membrane Antigen. J Urol 2003;170:1717-1721.

11. Bander, N.H., Nanus, D.M., Milowsky, M.I., Kostakoglu, L., Vallabahajosula, S., and Goldsmith, S.J.: Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate specific membrane antigen (PSMA). Seminars in Oncology 2003;30:667-677.

12. Vallabhajosula S, Kothari PA, Konishi S, Hamacher KA, Goldsmith SJ, Bander NH. Radiolabeled J591 antibody specific to prostate specific membrane antigen (PSMA): comparison of Indium-111, Yttrium-90 and Lutetium-177. J Label Radiopharma Compunds 2003;46:s313

13. Vallabahajosula S, Smith-Jones PM, Navarro V, Goldsmith SJ and Bander NH: Radioimmunotherapy Of Prostate Cancer In Human Xenografts Using Monoclonal Antibodies Specific To Prostate Specific Membrane Antigen (PSMA): Studies In Nude Mice. The Prostate 2004;58:145-155.

14. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH. Phase I Trial of 90Y-Labeled Anti-PSMA Monoclonal Antibody J591 For Androgen-Independent Prostate Cancer. J Clin Oncol 2004; J Clin Oncol 2004;22:2522-2531

15. Konishi S, Hamacher KA, Vallabhajosula S, Kothari P, Bastidas D, Bander NH, Goldsmith SJ. Determination of Immunoreactive Fraction of Radiolabeled MAbs: What is an Appropriate Method? Cancer Biother and Radiopharmma 2004;19:706-715

16. Vallabhajosula S, Kuji I, Hamacher KA, Konishi S, Kostakoglu L, Kothari PA, Milowski MI, Nanus DM, Bander NH. Goldsmith SJ. Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu? J Nucl Med 2005;46:634-641

17. Vallabhajosula S, Goldsmith SJ, Hamacher KA, Kostakoglu L, Konishi S, Milowski MI, Nanus DM, Bander NH. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. J Nucl Med 2005;46: 850-858

18. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I Trial of 177Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer. J Clin Oncol 2005;20;23(21): 4591-4601.

19. Vallabhajosula S, Goldsmith SJ, Kostakoglu L, Milowski MI, Nanus DM, Bander NH. Radioimmunotherapy of Prostate Cancer Using 90Y and 177Lu Labeled Antibodies: Effect of Multiple Treatments on Myelotoxicity Clin Cancer Res 2005;11:7195s-7200s